Hong Kong Stock Movement | Xuanzhu Bioph-B (02575.HK) Surges Over 18%; Phase III Clinical Data of Anlanzole Sodium for Reflux Esophagitis Recently Presented at UEG Week
Zhitong Finance APP has learned that Xuanzhu Biopharma-B (02575.HK) rose more than 18%, up 18.5% as of press time, at HK$9.13, with a turnover of HK$21.216 million.
Latest
